Will Tandem Diabetes Care Experience a COVID-19 Slowdown?

Will Tandem Diabetes Care Experience a COVID-19 Slowdown?

Source: 
Motley Fool
snippet: 

Growth has come easily for Tandem Diabetes Care (NASDAQ:TNDM) in recent years. The insulin pump developer grew revenue from $107 million in 2017 to $362 million in 2019. Margins have also improved as the business has scaled. Gross profit soared from $44 million to $194 million in that span, while a full-year 2019 operating loss of $17 million marked a significant improvement from prior years.